AG 348

Drug Profile

AG 348

Alternative Names: AG-348

Latest Information Update: 29 Dec 2016

Price : $50

At a glance

  • Originator Agios Pharmaceuticals
  • Class Antianaemics; Small molecules
  • Mechanism of Action Pyruvate kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Inborn error metabolic disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Haemolytic anaemia

Most Recent Events

  • 15 Dec 2016 Updated efficacy data from the phase II DRIVE-PK trial in Haemolytic anaemia released by Agios Pharmaceuticals
  • 15 Dec 2016 Agios Pharmaceuticals completes enrolment in its phase II DRIVE PK trial for Haemolytic anaemia in USA (NCT02476916)
  • 04 Dec 2016 Efficacy, pharmacodynamics and adverse events data from the phase II DRIVE-PK trial in Haemolytic anaemia (associated with pyruvate kinase deficiency) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top